Superworth

Metagenomi Therapeutics price to sales ratio MGX

Market value divided by revenue over the last twelve months, since 2025.

Today, Oct 23, 2026
n/m
a quarter missing
Peer median
1.4×

Metagenomi Therapeutics' price to sales ratio can't be checked today: its revenue for Q2 FY26, the quarter to Jun 30, 2026, is missing from our data, so the twelve months it rests on can't be added up.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.4×1.3×2.3×
20252.1×1.0×3.4×

Against its peers

Companies in Healthcare nearest Metagenomi Therapeutics' size, closest first, today.

CompanyPrice to sales ratio
MGXMetagenomi Therapeuticsn/m
NEPHNephros1.9×
ATNMActinium Pharmaceuticalsn/m
APTAlpha Pro Tech0.9×
SPROSpero Therapeutics1.4×
LFVNLifevantage0.4×
ICCCImmucell3.0×
KEQUKewaunee Scientific0.3×
PDEXPro DEX2.6×
PLXProtalix BioTherapeutics2.5×
NATRNatures Sunshine Products0.4×
Peer median1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Metagenomi Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.